Antidepressants: Pharmacy Medical Necessity Criteria for Brands
Customize your policy alerts
Sign up for Premera Bluecross Policy 5.01.520 alerts
Get alerted when Policy 5.01.520 changes without checking for updates manually.
Monitor payer policy activity
Defines when brand-name second‑generation antidepressant drugs (SSRIs, SNRIs, and related agents) are considered medically necessary for treatment of anxiety and related indications for Premera Blue Cross members and guides provider prior authorization decisions.
No material clinical or coverage changes in this revision.
Coverage Criteria for Brand Second‑Generation Antidepressants
This Introduction provides general background on antidepressant drug classes and the policy’s purpose and is not itself a set of coverage criteria. It explains that second‑generation antidepressants include SSRIs and SNRIs, that these agents exist in both brand and generic forms, and that generics are typically tried first because their active ingredients are chemically identical to brands. The remainder of the policy defines when brand-name second‑generation antidepressants may be considered medically necessary and how providers should document requests.
inv-02: Initial authorization criteria for branded antidepressants
Covered when ANY of the following prior trial patterns are documented:
Chunk support: 18,22
Chunk support: 18,22
Chunk support: 18,22
inv-03: Brand antidepressant coverage criteria
Covered when ONE of the following prior-treatment patterns is documented:
examples listed in document
examples listed in document
inv-04: Initial coverage criteria for listed brand antidepressants
Covered when ONE of the following prior-trial conditions is met
examples listed in chunks 54, 57, 63
referenced repeatedly in chunks 54-73
inv-05: Prior drug trial criteria for brand antidepressants
Covered when the following prior drug trial conditions are met for branded antidepressants:
Examples of generic agents are listed in text; condition-specific exceptions reference Related Policies for neuropathic or pain indications.
inv-06: Branded products list
Products listed under the branded antidepressant policy:
Brand list repeats across document segments.
inv-07: Initial therapy/coverage criterion
Covered when ALL of the following are met
Referenced repeatedly in document
inv-08: Initial therapy/brand coverage criteria
Covered when ALL of the following are met
This requirement is stated repeatedly for the listed brand products
inv-09: Initial coverage criteria for brand antidepressants
Covered when ALL of the following are met
This requirement is repeated for multiple listed brand agents
inv-10: Initial coverage criteria for brand antidepressants
Covered when ALL of the following are met
Applies to the listed brand antidepressant agents
Full list appears across chunks 144–163
inv-11: Initial coverage criteria
Covered when ALL of the following are met
Required prior to branded antidepressant coverage
List in document is repetitive and illustrative rather than exhaustive
inv-12: Brand antidepressant initial coverage criteria
Covered when ALL of the following are met
Required prior therapy before brand coverage
Pain indications handled in separate Depression criteria
inv-13: Branded antidepressant listing and indication cross-reference
Covered when matching branded antidepressant meets policy criteria
drug list repeated across chunks
refer to separate policy for pain indications
inv-14: Listed Brand Antidepressants
Covered brands and referenced step/level positions
Exact clinical criteria and step/level logic (1,2,3) referenced but not provided in this excerpt.
inv-15: Initial coverage criteria for listed brand antidepressants
Brand antidepressants may be considered medically necessary when product-specific criteria are met; many brands require antecedent trials of generic agents:
Referenced for multiple listed brand products (e.g., Auvelity, Exxua, Fetzima, Lexapro, Paxil, Pristiq, Prozac, Trintellix, Raldesy).
Dose/quantity limits appear in multiple chunks for specific products.
inv-16: Coverage criteria for Exxua (gepirone)
Exxua (gepirone) for depression may be considered medically necessary when ALL of the following are met:
examples of generic agents are illustrative; documentation of trials required.
For requests for treatment of diabetic peripheral neuropathy, chronic musculoskeletal pain, or fibromyalgia, refer to the related policies rather than the brand antidepressant criteria in this section. The policy repeatedly notes that coverage for those pain-related diagnoses follows separate, indication-specific guidance (see referenced Related Policies).
This section does not establish coverage rules for pain-related uses of SNRIs. If the indication is diabetic peripheral neuropathy, chronic musculoskeletal pain, or fibromyalgia, providers must follow the related Depression/Aplenzin ER policy and other referenced Related Policies for diagnosis‑specific criteria.
Cross-reference: requests for branded antidepressants intended for diabetic peripheral neuropathy, chronic musculoskeletal pain, or fibromyalgia should be submitted under the Depression/pain-specific policy cited in the document rather than evaluated under these general brand antidepressant criteria.
Provider Actions, Prior Authorization & Documentation
Prior authorization required for brand antidepressants
Prior authorization is required for brand second‑generation antidepressants when used to treat anxiety unless documentation shows the required generic trials and failures.
Required prior generic SSRI/SNRI trials
Prior authorization requires documentation that the member has had trial and failure of two generic SSRIs, OR two generic SNRIs, OR one generic SSRI and one generic SNRI before a branded antidepressant will be approved.
Prior authorization — SNRI or SSRI+SNRI trials required
Prior authorization for listed branded antidepressants requires documentation of trial and failure of either two generic SNRIs OR one generic SSRI and one generic SNRI before coverage is granted.
Document required SNRI or SSRI+SNRI failures
Prior authorization requires evidence of trial and failure of either two generic SNRIs (examples: desvenlafaxine, duloxetine, venlafaxine) OR one generic SSRI plus one generic SNRI.
- Generic SNRI examples listed: desvenlafaxine, duloxetine, venlafaxine.
Prior authorization and dose/quantity limits for Exxua (gepirone)
For Exxua (gepirone), prior authorization requires documentation of trial and failure of two generic second‑generation antidepressants; dosing is limited to 72.6 mg/day and quantity limited to 1 tablet/day.
- Dose limit: 72.6 mg per day.
- Quantity limit: 1 tablet per day.
Step therapy: generic SSRI/SNRI trials required prior to brand
Step therapy requires documented trial and failure of two generic SSRIs OR two generic SNRIs OR one generic SSRI and one generic SNRI before a brand second‑generation antidepressant will be considered medically necessary for anxiety.
Denial risk for missing generic trial documentation
If trials and failures of the required generic agents are not documented, the prior authorization request may be denied.
- Failure to document trials and failures of required generics is a grounds for denial.
Denial risk for not meeting prior trial requirements
Coverage may be denied if the individual has not had the required number and type of prior generic SSRI or SNRI trials (examples and options are stated in the policy).
Required documentation of prior generic SSRI/SNRI trials
Providers must document prior trials and failures of the specified generic SSRIs and/or SNRIs (examples listed in the policy include citalopram, escitalopram, fluoxetine, paroxetine, sertraline; desvenlafaxine, duloxetine, venlafaxine).
- Include drug names, dates of use, reason for discontinuation (lack of efficacy or intolerance), and duration of trial where available.
Provide drug identification and proof of prior trials
Prescribers should identify the specific branded product requested and support the request with proof of the prior trials and current dosing; failure to provide required trial documentation may result in denial.
- List the exact brand name on the prior authorization request.
- Attach clinical notes showing trials/failures of the generic agents and current prescribed dose.
Initial Therapy Requirements
inv-115: Initial therapy requirements
Covered when ALL of the following are met
Examples of generic agents provided in policy text.
inv-116: Initial therapy requirements
Initial coverage of branded antidepressants requires prior trials of generics.
Chunks 18,22
Chunks 18,22
Chunks 18,22
inv-117: Initial therapy prior trials
Initial coverage for listed brand antidepressants requires documented prior trials:
inv-118: Prior trials before brand coverage
Initial authorization requires prior trials of generics
chunks 54,57
chunks 54-63
inv-119: Initial therapy prior-trial requirements
Initial coverage requires documented prior trials
Generic examples provided (desvenlafaxine, duloxetine, venlafaxine); exceptions for pain conditions referenced to Related Policies.
inv-120: Initial therapy
Initial coverage requirement for branded antidepressants in this section
See Related Policies for pain indications
inv-121: Initial therapy
Initial coverage for listed brand antidepressants
Repeated across chunks; required prior to brand coverage
inv-122: Initial therapy
Initial authorization requirement
Applies to requests for the listed brand antidepressants
inv-123: Initial therapy requirements
Initial (brand) therapy requires documented prior trials
Required before initiating listed brand antidepressants
inv-124: Initial therapy for branded antidepressants
Applies before branded product coverage
inv-125: Initial therapy requirements
Initial coverage for brands
Applies to brand antidepressants
inv-126: Initial therapy — branded list
Initial therapy listing
explicit initial authorization rules not present in these chunks
inv-127: Initial therapy (levels referenced)
Initial use references numeric levels
Full initial therapy criteria not present in provided chunks.
inv-128: Initial therapy requirements
Initial coverage for many brand antidepressants
Listed as a condition for medical necessity for multiple brands.
inv-129: Initial therapy for Exxua
Initial coverage consideration for Exxua (gepirone):
Step Therapy Requirements
| Step | Requirement |
|---|---|
| 1 | |
| Must document prior trials and failures of required generic SSRIs and/or SNRIs (per policy) before a branded second‑generation antidepressant is approved. |
| Step | Requirement |
|---|---|
| 1 | |
| Step therapy enforces trials of generic SSRIs and/or SNRIs (examples listed) prior to coverage of listed branded antidepressants. |
| Step | Requirement |
|---|---|
| 1 | |
| Trial and documented failure of specified generic agents is required before coverage of branded antidepressants (options include two generic SNRIs OR one generic SSRI plus one generic SNRI). |
| Step | Requirement |
|---|---|
| Step 1 | |
| Member must trial and fail either two generic SNRIs OR one generic SSRI plus one generic SNRI before a branded antidepressant will be approved. |
| Step | Requirement |
|---|---|
| 1 | |
| Prior trial(s) of specified generic SSRIs and/or SNRIs are required before accessing branded antidepressant coverage. |
| Step | Requirement |
|---|---|
| 1 | |
| Must try and fail one generic SSRI and one generic SNRI prior to coverage of many listed branded antidepressants (documentation required). |
| Step | Requirement |
|---|---|
| 1 | |
| Member must have failed both classes (at least one SSRI and one SNRI) before a brand antidepressant is covered. |
| Step | Requirement |
|---|---|
| 1 | |
| Must document trials of one generic SSRI and one generic SNRI before approving the listed brand antidepressants; absence of documentation may trigger denial. |
| Step | Requirement |
|---|---|
| 1 | |
| Must document failure of the required generic SSRI and SNRI prior to approval of the brand agent (documentation of trial and failure required). |
| Step | Requirement |
|---|---|
| 1 | |
| Member must have documented trials of at least one generic SSRI and one generic SNRI before the branded agent will be covered. |
| Step | Requirement |
|---|---|
| 1 | |
| Must fail the specified generics (one SSRI and one SNRI) before a branded antidepressant is authorized; lack of trials may result in denial. |
| Observation | Note |
|---|---|
| Numeric markers adjacent to drug lists | |
| Numeric markers (1,2,3) appear beside many drug entries and likely indicate step/tier positions; explicit step therapy rules for those numbered levels are not fully provided in the cited sections. |
| Observation | Note |
|---|---|
| Referenced step/level structure | |
| The document references numeric steps/levels (1,2,3) for second‑generation antidepressants, but detailed step therapy requirements and failure criteria are described elsewhere and not fully duplicated with the level markers in these excerpts. |
| Step | Requirement |
|---|---|
| 1 | |
| Required prior trials of two generic second‑generation antidepressants are necessary before coverage of several listed brand agents (examples include fluoxetine, sertraline, venlafaxine, bupropion, mirtazapine). |
| Step | Requirement |
|---|---|
| 1 | |
| Coverage for Exxua (gepirone) requires documentation of trials and failures of two generic second‑generation antidepressants and adherence to product dose/quantity limits (dose limited to 72.6 mg/day; quantity limited to 1 tablet/day). |
Dose and Quantity Limits
Product-Specific Quantity Limits
Definitions and Examples
Background
Background: Second‑generation antidepressants (SSRIs and SNRIs) are commonly used to treat anxiety disorders and largely replaced earlier first‑generation agents (MAOIs and TCAs). Brand and generic formulations contain the same active ingredients; generics are typically tried first, and this policy specifies when branded formulations may be considered medically necessary after appropriate generic trials and documented failures.
Revision History
Policy 5.01.520 became effective on 2026-07-01.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.